Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

NCT04526795 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

19

Enrollment

OTHER

Sponsor class

Stopped Administratively Complete

Conditions

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Acute Biphenotypic Leukemia
Recurrent Acute Lymphoblastic Leukemia
Recurrent Acute Myeloid Leukemia
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent T-Cell Prolymphocytic Leukemia
Refractory Acute Biphenotypic Leukemia
Refractory Acute Lymphoblastic Leukemia
Refractory Acute Myeloid Leukemia
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Refractory T-Cell Prolymphocytic Leukemia

Interventions

DRUG: Cytarabine
DRUG: Fludarabine
DRUG: Pegcrisantaspase

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]